JAGX

Jaguar HealthF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$0.90

-68.0% vs current

Most likely

Base case

45%

Probability

Target price

$0.38

-86.5% vs current

B-

Bear case

35%

Probability

Target price

$0.12

-95.7% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Sentiment is best framed as cautious monitoring, not a clean bullish setup. The April 2026 8-K removed some immediate balance-sheet pressure by asserting restored equity above Nasdaq's minimum, but the 10-K still carries going-concern language and the equity story remains dependent on follow-through cash receipts and speculative rare-disease trial progress [#8-K-2026-04-09][#10-K-2026-04-07].

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventFuture Pak post-closing cash receipts and initial product sales need to convert from promise to cashHigh impact

Primary sources point to a remaining $2 million payment upon completion of post-closing conditions, approximately $1.2 million from a firm Mytesi product order, and additional commercialization-linked payments under the January 12, 2026 licensing arrangement. Receipt timing matters because the 10-K still says the company lacks sufficient cash resources to fund operations through March 2027 [#8-K-2026-04-09][#10-K-2026-04-07][#PR-2026-01-12].

2026-06-30catalystNasdaq equity compliance remains a live near-term swing factorHigh impact

The April 9, 2026 8-K says Jaguar had an approximately $18.7 million stockholders' deficit at December 31, 2025, but believes stockholders' equity exceeded the Nasdaq $2.5 million minimum by April 7, 2026 after the January licensing deal, related cash receipts, expected post-closing proceeds, inventory sales, grant revenue, and debt extinguishment. Confirmation that Nasdaq accepts this recovery would ease an acute overhang; failure would keep listing risk front and center [#8-K-2026-04-09].

2026-06-30catalystMVID Phase 2 completion is the only clear operating upside hook, but it is still highly speculativeHigh impact

Jaguar said on January 22, 2026 that its placebo-controlled Phase 2 trial of crofelemer in pediatric MVID is expected to complete in Q2 2026, and that positive results plus the amended protocol could support a faster FDA path and possible Breakthrough Therapy and EMA PRIME discussions. This is the main program-level upside driver, but it remains contingent on small-study clinical execution and favorable data [#PR-2026-01-22][#PR-2026-01-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology